Soleno Therapeutics Inc

Company Profile

Soleno Therapeutics Inc had its IPO on 2014-11-13 under the ticker symbol SLNO.

The company operates in the Healthcare sector and Biotechnology industry. Soleno Therapeutics Inc has a staff strength of 25 employees.

Stock update

Shares of Soleno Therapeutics Inc opened at $4.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.82 - $4.21, and closed at $4.

This is a -2.68% slip from the previous day's closing price.

A total volume of 62,210 shares were traded at the close of the day’s session.

In the last one week, shares of Soleno Therapeutics Inc have slipped by -19.68%.

Soleno Therapeutics Inc's Key Ratios

Soleno Therapeutics Inc has a market cap of $41.07 million, indicating a price to book ratio of 0.4939 and a price to sales ratio of 0.

In the last 12-months Soleno Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-26836000. The EBITDA ratio measures Soleno Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Soleno Therapeutics Inc’s operating margin was 0% while its return on assets stood at -53.08% with a return of equity of -173.82%.

In Q2, Soleno Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Soleno Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-2.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Soleno Therapeutics Inc’s profitability.

Soleno Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5162. Its price to sales ratio in the trailing 12-months stood at 0.

Soleno Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$30.94 million

Total Liabilities

$8.80 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Soleno Therapeutics Inc ended 2023 with $30.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.94 million while shareholder equity stood at $12.43 million.

Soleno Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $8.80 million in other current liabilities, 10000.00 in common stock, $-254253000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.37 million and cash and short-term investments were $19.37 million. The company’s total short-term debt was $212,000 while long-term debt stood at $0.

Soleno Therapeutics Inc’s total current assets stands at $20.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.44 million and inventory worth $0.

In 2023, Soleno Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Soleno Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$4

52-Week High

$6.2

52-Week Low

$0.85

Analyst Target Price

$12.33

Soleno Therapeutics Inc stock is currently trading at $4 per share. It touched a 52-week high of $6.2 and a 52-week low of $6.2. Analysts tracking the stock have a 12-month average target price of $12.33.

Its 50-day moving average was $4.75 and 200-day moving average was $3.38 The short ratio stood at 2.86 indicating a short percent outstanding of 0%.

Around 1099.2% of the company’s stock are held by insiders while 6635.8% are held by institutions.